Veradermics to Present at the Jefferies Global Healthcare Conference in London
Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss - Slideshow
Veradermics: Q3 Earnings Snapshot
Citigroup Maintains Buy on Veradermics, Raises Price Target to $175
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript
Veradermics stock rises on 12-month hair growth trial data
Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150
Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics (MANE) Late Stage Trial Narrative Keeps Undervalued View Alive
Why This Hair Restoration Biotech's Shares Are Soaring
B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
Veradermics’ stock up on male hair loss trial success
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.